Ad
INCY - Incyte Corporation Stock Trading
News, Short Squeeze, Breakout and More Instantly...
Ad
Ad
-
Total revenues increased 29% year-over-year (Y/Y) to $911 million; total product revenues of $664 million (+15% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $598 million in Q2’22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year g...
-
The stock market has been unpredictable and volatile all year long. All three major U.S. market indexes are in the red, and with economic problems still at the forefront of everyone's minds, no one knows when things will get better. Amid these issues, some stocks have performed surprisi...
-
Opzelura is the first and only FDA-approved product for repigmentation in nonsegmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation Fifty-two week data demonstrate ...
Ad
